Nailed it with the timelines!!!!!!!!!! LooooooooooooooooooL
Nicholas,
Thank you for your email.
I understand that you are limited in what your responses may divulge, however you mentioned that you could discuss each asset and a timeline.
I would be very curious to hear back from you on Farmako, E&I, Delta, AAA.
Farmako: Currently Farmako is our only revenue generating asset. You can see results for the first quarter this year in our quarterly release which should be released on or before July 16th . Farmako is now a top three distributor of medical cannabis in Germany. They are also licensed in the UK which is still in the very early stages of the medical market. Farmako has a new supply deal with Zenabis and is moving forward with Famrako branded oils soon and the expectation is an EU-GMP certification by year’s end.
EIC: EIC is a great asset. A processing license has been submitted and the company expects receipt before Q4. Between now and then, R&D trials as well as supply agreements will be put in place. The intention will be that the company can begin revenue generation immediately after receiving the license. I would expect that there will be several catalysts between now and the beginning of Q4.
Delta: The delta facility is currently in the first stages of cultivation. I would expect to be able to show plants in the next week or two. There are active dialogues with partners for supply agreements and the expectation is that we will have our first harvest spoken for. We currently don’t need a sale license to execute on our business strategy at Delta. Our strategy hinges around B2B sales. The focus will be high quality, high potency and low-cost cannabis flower. I would say first sales would happen mid Q4.
AAA: this asset has been placed on care and maintenance. While a good quality asset, the high operating costs and saturated craft market make it difficult to justify operations. We will either re-assess this project at a later date or sell to someone with a craft focus.
SGSC: Our extraction facility in Toronto for high quality CBD Hemp Crude, Distillate and Isolate products will be our second revenue generator this year. I would expect this quarter we will see revenue generation. Keep an eye out for supply contracts and farm developments. This B2B strategy will service a market that is underserviced. Quality CBD hemp and THC less product is surging in demand.